205 related articles for article (PubMed ID: 18322400)
1. M1 muscarinic agonists target major hallmarks of Alzheimer's disease--the pivotal role of brain M1 receptors.
Fisher A
Neurodegener Dis; 2008; 5(3-4):237-40. PubMed ID: 18322400
[TBL] [Abstract][Full Text] [Related]
2. M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update.
Fisher A
Curr Alzheimer Res; 2007 Dec; 4(5):577-80. PubMed ID: 18220527
[TBL] [Abstract][Full Text] [Related]
3. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.
Fisher A; Pittel Z; Haring R; Bar-Ner N; Kliger-Spatz M; Natan N; Egozi I; Sonego H; Marcovitch I; Brandeis R
J Mol Neurosci; 2003; 20(3):349-56. PubMed ID: 14501019
[TBL] [Abstract][Full Text] [Related]
4. M1 receptors play a central role in modulating AD-like pathology in transgenic mice.
Caccamo A; Oddo S; Billings LM; Green KN; Martinez-Coria H; Fisher A; LaFerla FM
Neuron; 2006 Mar; 49(5):671-82. PubMed ID: 16504943
[TBL] [Abstract][Full Text] [Related]
5. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.
Fisher A; Brandeis R; Bar-Ner RH; Kliger-Spatz M; Natan N; Sonego H; Marcovitch I; Pittel Z
J Mol Neurosci; 2002; 19(1-2):145-53. PubMed ID: 12212772
[TBL] [Abstract][Full Text] [Related]
6. Beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling.
Züchner T; Perez-Polo JR; Schliebs R
J Neurosci Res; 2004 Jul; 77(2):250-7. PubMed ID: 15211591
[TBL] [Abstract][Full Text] [Related]
7. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease.
Nitsch RM; Deng M; Tennis M; Schoenfeld D; Growdon JH
Ann Neurol; 2000 Dec; 48(6):913-8. PubMed ID: 11117548
[TBL] [Abstract][Full Text] [Related]
8. Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: an unifying hypothesis.
Fisher A; Brandeis R; Haring R; Eshhar N; Heldman E; Karton Y; Eisenberg O; Meshulam H; Marciano D; Bar-Ner N; Pittel Z
J Physiol Paris; 1998; 92(5-6):337-40. PubMed ID: 9789833
[TBL] [Abstract][Full Text] [Related]
9. AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer’s Disease.
Fisher A; Bezprozvanny I; Wu L; Ryskamp DA; Bar-Ner N; Natan N; Brandeis R; Elkon H; Nahum V; Gershonov E; LaFerla FM; Medeiros R
Neurodegener Dis; 2016; 16(1-2):95-110. PubMed ID: 26606130
[TBL] [Abstract][Full Text] [Related]
10. Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models.
Chandra JN; Malviya M; Sadashiva CT; Subhash MN; Rangappa KS
Neurochem Int; 2008 Feb; 52(3):376-83. PubMed ID: 17719699
[TBL] [Abstract][Full Text] [Related]
11. [Selective M1 muscarinic agonists: failure of therapeutic strategy against Alzheimer's disease or inappropriate tactics?].
Vamvakidès A
Ann Pharm Fr; 2003 May; 61(3):207-10. PubMed ID: 12714934
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists.
Fisher A
Jpn J Pharmacol; 2000 Oct; 84(2):101-12. PubMed ID: 11128032
[TBL] [Abstract][Full Text] [Related]
13. Muscarinic agonists as preventative therapy for Alzheimer's disease.
Beach TG
Curr Opin Investig Drugs; 2002 Nov; 3(11):1633-6. PubMed ID: 12476965
[TBL] [Abstract][Full Text] [Related]
14. Acute Effects of Muscarinic M1 Receptor Modulation on AβPP Metabolism and Amyloid-β Levels in vivo: A Microdialysis Study.
Welt T; Kulic L; Hoey SE; McAfoose J; Späni C; Chadha AS; Fisher A; Nitsch RM
J Alzheimers Dis; 2015; 46(4):971-82. PubMed ID: 25881909
[TBL] [Abstract][Full Text] [Related]
15. Impact of muscarinic agonists for successful therapy of Alzheimer's disease.
Fisher A; Brandeis R; Haring R; Bar-Ner N; Kliger-Spatz M; Natan N; Sonego H; Marcovitch I; Pittel Z
J Neural Transm Suppl; 2002; (62):189-202. PubMed ID: 12456063
[TBL] [Abstract][Full Text] [Related]
16. Differences in regional and subcellular localization of G(q/11) and RGS4 protein levels in Alzheimer's disease: correlation with muscarinic M1 receptor binding parameters.
Muma NA; Mariyappa R; Williams K; Lee JM
Synapse; 2003 Jan; 47(1):58-65. PubMed ID: 12422374
[TBL] [Abstract][Full Text] [Related]
17. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives.
Fisher A; Michaelson DM; Brandeis R; Haring R; Chapman S; Pittel Z
Ann N Y Acad Sci; 2000; 920():315-20. PubMed ID: 11193170
[TBL] [Abstract][Full Text] [Related]
18. Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists.
Beach TG; Walker DG; Potter PE; Sue LI; Fisher A
Brain Res; 2001 Jun; 905(1-2):220-3. PubMed ID: 11423097
[TBL] [Abstract][Full Text] [Related]
19. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation.
Song MS; Rauw G; Baker GB; Kar S
Eur J Neurosci; 2008 Nov; 28(10):1989-2002. PubMed ID: 19046381
[TBL] [Abstract][Full Text] [Related]
20. Progress in medicinal chemistry of novel selective muscarinic agonists.
Fisher A; Karton Y; Heldman E; Gurwitz D; Haring R; Meshulam H; Brandeis R; Pittel Z; Segall Y; Marciano D
Drug Des Discov; 1993; 9(3-4):221-35. PubMed ID: 8400004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
